AstraZeneca PLC - SWOT, Strategy and Corporate Finance Report
Published: June 2013 · Publisher: MarketLine
AstraZeneca PLC - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc.
- Description
- Table of Contents
- Ask a Question
AstraZeneca PLC - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.
Features:
- Detailed information on AstraZeneca PLC required for business and competitor intelligence needs
- A study of the major internal and external factors affecting AstraZeneca PLC in the form of a SWOT analysis
- An in-depth view of the business model of AstraZeneca PLC including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for AstraZeneca PLC
- Intelligence on AstraZeneca PLCnv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about AstraZeneca PLC, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:
AstraZeneca PLC (AstraZeneca or 'the company') is a UK-based global biopharmaceutical company. The company is engaged in developing, manufacturing, and marketing prescription pharmaceuticals in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory, inflammation, and infection. AstraZeneca operates in the Americas, Europe and Asia. The company is headquartered in London, the UK, and employed about 53,500 people as of December 31, 2012. The company recorded revenues of $27,973 million during the financial year ended December 2012 (FY2012), a decrease of 16.7% over FY2011. The operating profit of the company was $8,148 million in FY2012, a decrease of 36.3% over FY2011. The net profit was $6,297 million in FY2012, a decrease of 36.9% over FY2011.
Reasons to Purchase:
- Gain understanding of AstraZeneca PLC and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess AstraZeneca PLC as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on AstraZeneca PLC’s business structure, strategy and prospects
Features:
- Detailed information on AstraZeneca PLC required for business and competitor intelligence needs
- A study of the major internal and external factors affecting AstraZeneca PLC in the form of a SWOT analysis
- An in-depth view of the business model of AstraZeneca PLC including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for AstraZeneca PLC
- Intelligence on AstraZeneca PLCnv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about AstraZeneca PLC, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:
AstraZeneca PLC (AstraZeneca or 'the company') is a UK-based global biopharmaceutical company. The company is engaged in developing, manufacturing, and marketing prescription pharmaceuticals in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory, inflammation, and infection. AstraZeneca operates in the Americas, Europe and Asia. The company is headquartered in London, the UK, and employed about 53,500 people as of December 31, 2012. The company recorded revenues of $27,973 million during the financial year ended December 2012 (FY2012), a decrease of 16.7% over FY2011. The operating profit of the company was $8,148 million in FY2012, a decrease of 36.3% over FY2011. The net profit was $6,297 million in FY2012, a decrease of 36.9% over FY2011.
Reasons to Purchase:
- Gain understanding of AstraZeneca PLC and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess AstraZeneca PLC as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on AstraZeneca PLC’s business structure, strategy and prospects
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Company Snapshot
AstraZeneca PLC: Company Overview
AstraZeneca PLC: Overview and Key Facts
AstraZeneca PLC: Overview
AstraZeneca PLC: Key Facts
AstraZeneca PLC: Key Employees
AstraZeneca PLC: Key Employee Biographies
AstraZeneca PLC: Major Products and Services
AstraZeneca PLC: Company History
AstraZeneca PLC: Management Statement
AstraZeneca PLC: Locations and Subsidiaries
AstraZeneca PLC: Key Competitors
AstraZeneca PLC: Company Analysis
AstraZeneca PLC: Business Description
AstraZeneca PLC: SWOT Analysis
AstraZeneca PLC: SWOT Overview
AstraZeneca PLC: Strengths
AstraZeneca PLC: Weaknesses
AstraZeneca PLC: Opportunities
AstraZeneca PLC: Threats
AstraZeneca PLC: Financial Analysis
AstraZeneca PLC: Financial Overview
AstraZeneca PLC: Five Year Company Financials
AstraZeneca PLC: Key Income Statement Data
AstraZeneca PLC: Key Balance Sheet Data
AstraZeneca PLC: Key Cash Flow Data
AstraZeneca PLC: Key Market Data
AstraZeneca PLC: Valuation Ratios
AstraZeneca PLC: Profitability Ratios
AstraZeneca PLC: Management Efficiency Ratios
AstraZeneca PLC: Financial Strength Ratios
AstraZeneca PLC: Operational Efficiency Ratios
AstraZeneca PLC: Others
AstraZeneca PLC: Corporate Financial Deals Activity
AstraZeneca PLC: Financial Deals Overview
AstraZeneca PLC: Targets and Partners
AstraZeneca PLC: Top Deals 2009 - 2013YTD*
AstraZeneca PLC: Advisors
AstraZeneca PLC: Top Legal Advisors
AstraZeneca PLC: Top Financial Advisors
AstraZeneca PLC: Mergers and Acquisitions
AstraZeneca PLC: Partnership
AstraZeneca PLC: Divestments
AstraZeneca PLC: Recent Developments
AstraZeneca PLC: News and Events Summary
AstraZeneca PLC: Business Expansion
AstraZeneca PLC: Contracts
AstraZeneca PLC: Financial Performance
AstraZeneca PLC: Regulatory and Legal Events
AstraZeneca PLC: Research & Development
Appendix
Contact Us
Methodology
Definitions
List of Tables
Table 1: AstraZeneca PLC: Key Facts
Table 2: AstraZeneca PLC: Key Employees
Table 4: AstraZeneca PLC: Key Competitors
Table 5: AstraZeneca PLC: Key Income Statement Data
Table 6: AstraZeneca PLC: Key Balance Sheet Data
Table 7: AstraZeneca PLC: Key Cash Flow Data
Table 8: AstraZeneca PLC: Key Market Data
Table 9: AstraZeneca PLC: Key Growth Ratios
Table 10: AstraZeneca PLC: Valuation Ratios
Table 11: AstraZeneca PLC: Profitability Ratios
Table 12: AstraZeneca PLC: Management Efficiency Ratios
Table 13: AstraZeneca PLC: Financial Strength Ratios
Table 14: AstraZeneca PLC: Operational Efficiency Ratios
Table 15: AstraZeneca PLC: Others
Table 16: AstraZeneca PLC: Deal Activity by Deal Type - Volume (TTM*)
Table 17: AstraZeneca PLC: M&A Activity by Geography (TTM*)
Table 18: AstraZeneca PLC: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Table 19: AstraZeneca PLC: M&A Average Deal Size - Value (US$m)
Table 20: AstraZeneca PLC: Targets and Partners
Table 21: AstraZeneca PLC: Top Deals 2009 - 2013YTD*
Table 22: AstraZeneca PLC: Legal Advisor Ranking by Value (US$m)
Table 23: AstraZeneca PLC: Financial Advisor Ranking by Value (US$m)
Table 24: AstraZeneca PLC: M&A Volume and Value Trend (2009 - YTD*2013)
Table 25: AstraZeneca PLC: M&A Activity by Geography (2009 - YTD*2013)
Table 26: AstraZeneca PLC: Partnership Volume and Value Trend (2009 - YTD*2013)
Table 27: AstraZeneca PLC: Partnership Trend by Deal Type (2009 - YTD*2013)
Table 28: AstraZeneca PLC: Divestments Volume and Value Trend (2009 - YTD*2013)
Table 29: AstraZeneca PLC: Divestments by Geography (2009 - YTD*2013)
Table 30: AstraZeneca PLC: News and Events Summary
Table 31: AstraZeneca PLC: Business Expansion
Table 32: AstraZeneca PLC: Contracts
Table 33: AstraZeneca PLC: Financial Performance
Table 34: AstraZeneca PLC: Regulatory and Legal Events
Table 35: AstraZeneca PLC: Research & Development
List of Figures
Figure 1: AstraZeneca PLC: Revenue to Net Income (2007-2011)
Figure 2: AstraZeneca PLC: Revenue/Employee to Net Income/Employee (2007-2011)
Figure 3: AstraZeneca PLC: Current Assets to Current Liabilities (2007-2011)
Figure 4: AstraZeneca PLC: Assets, Liabilities to Total Equity (2007-2011)
Figure 5: AstraZeneca PLC: Free Cash Flow to Cash from Operating Activities (2007-2011)
Figure 6: AstraZeneca PLC: Net Change in Cash (2007-2011)
Figure 7: AstraZeneca PLC: Market Capitalization to Year-end Share Price (2007-2011)
Figure 8: AstraZeneca PLC: Enterprise Value (2007-2011)
Figure 9: AstraZeneca PLC: Deal Activity by Deal Type - Volume (TTM*)
Figure 10: AstraZeneca PLC: M&A Activity by Geography (TTM*)
Figure 11: AstraZeneca PLC: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Figure 12: AstraZeneca PLC: M&A Average Deal Size - Value (US$m)
Figure 13: AstraZeneca PLC: M&A Volume and Value Trend (2009 - YTD*2013)
Figure 14: AstraZeneca PLC: M&A Activity by Geography (2009 - YTD*2013)
Figure 15: AstraZeneca PLC: Partnership Volume and Value Trend (2009 - YTD*2013)
Figure 16: AstraZeneca PLC: Partnership Trend by Deal Type (2009 - YTD*2013)
Figure 17: AstraZeneca PLC: Divestments Volume and Value Trend (2009 - YTD*2013)
Figure 18: AstraZeneca PLC: Divestments by Geography (2009 - YTD*2013)
AstraZeneca PLC: Company Overview
AstraZeneca PLC: Overview and Key Facts
AstraZeneca PLC: Overview
AstraZeneca PLC: Key Facts
AstraZeneca PLC: Key Employees
AstraZeneca PLC: Key Employee Biographies
AstraZeneca PLC: Major Products and Services
AstraZeneca PLC: Company History
AstraZeneca PLC: Management Statement
AstraZeneca PLC: Locations and Subsidiaries
AstraZeneca PLC: Key Competitors
AstraZeneca PLC: Company Analysis
AstraZeneca PLC: Business Description
AstraZeneca PLC: SWOT Analysis
AstraZeneca PLC: SWOT Overview
AstraZeneca PLC: Strengths
AstraZeneca PLC: Weaknesses
AstraZeneca PLC: Opportunities
AstraZeneca PLC: Threats
AstraZeneca PLC: Financial Analysis
AstraZeneca PLC: Financial Overview
AstraZeneca PLC: Five Year Company Financials
AstraZeneca PLC: Key Income Statement Data
AstraZeneca PLC: Key Balance Sheet Data
AstraZeneca PLC: Key Cash Flow Data
AstraZeneca PLC: Key Market Data
AstraZeneca PLC: Valuation Ratios
AstraZeneca PLC: Profitability Ratios
AstraZeneca PLC: Management Efficiency Ratios
AstraZeneca PLC: Financial Strength Ratios
AstraZeneca PLC: Operational Efficiency Ratios
AstraZeneca PLC: Others
AstraZeneca PLC: Corporate Financial Deals Activity
AstraZeneca PLC: Financial Deals Overview
AstraZeneca PLC: Targets and Partners
AstraZeneca PLC: Top Deals 2009 - 2013YTD*
AstraZeneca PLC: Advisors
AstraZeneca PLC: Top Legal Advisors
AstraZeneca PLC: Top Financial Advisors
AstraZeneca PLC: Mergers and Acquisitions
AstraZeneca PLC: Partnership
AstraZeneca PLC: Divestments
AstraZeneca PLC: Recent Developments
AstraZeneca PLC: News and Events Summary
AstraZeneca PLC: Business Expansion
AstraZeneca PLC: Contracts
AstraZeneca PLC: Financial Performance
AstraZeneca PLC: Regulatory and Legal Events
AstraZeneca PLC: Research & Development
Appendix
Contact Us
Methodology
Definitions
List of Tables
Table 1: AstraZeneca PLC: Key Facts
Table 2: AstraZeneca PLC: Key Employees
Table 4: AstraZeneca PLC: Key Competitors
Table 5: AstraZeneca PLC: Key Income Statement Data
Table 6: AstraZeneca PLC: Key Balance Sheet Data
Table 7: AstraZeneca PLC: Key Cash Flow Data
Table 8: AstraZeneca PLC: Key Market Data
Table 9: AstraZeneca PLC: Key Growth Ratios
Table 10: AstraZeneca PLC: Valuation Ratios
Table 11: AstraZeneca PLC: Profitability Ratios
Table 12: AstraZeneca PLC: Management Efficiency Ratios
Table 13: AstraZeneca PLC: Financial Strength Ratios
Table 14: AstraZeneca PLC: Operational Efficiency Ratios
Table 15: AstraZeneca PLC: Others
Table 16: AstraZeneca PLC: Deal Activity by Deal Type - Volume (TTM*)
Table 17: AstraZeneca PLC: M&A Activity by Geography (TTM*)
Table 18: AstraZeneca PLC: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Table 19: AstraZeneca PLC: M&A Average Deal Size - Value (US$m)
Table 20: AstraZeneca PLC: Targets and Partners
Table 21: AstraZeneca PLC: Top Deals 2009 - 2013YTD*
Table 22: AstraZeneca PLC: Legal Advisor Ranking by Value (US$m)
Table 23: AstraZeneca PLC: Financial Advisor Ranking by Value (US$m)
Table 24: AstraZeneca PLC: M&A Volume and Value Trend (2009 - YTD*2013)
Table 25: AstraZeneca PLC: M&A Activity by Geography (2009 - YTD*2013)
Table 26: AstraZeneca PLC: Partnership Volume and Value Trend (2009 - YTD*2013)
Table 27: AstraZeneca PLC: Partnership Trend by Deal Type (2009 - YTD*2013)
Table 28: AstraZeneca PLC: Divestments Volume and Value Trend (2009 - YTD*2013)
Table 29: AstraZeneca PLC: Divestments by Geography (2009 - YTD*2013)
Table 30: AstraZeneca PLC: News and Events Summary
Table 31: AstraZeneca PLC: Business Expansion
Table 32: AstraZeneca PLC: Contracts
Table 33: AstraZeneca PLC: Financial Performance
Table 34: AstraZeneca PLC: Regulatory and Legal Events
Table 35: AstraZeneca PLC: Research & Development
List of Figures
Figure 1: AstraZeneca PLC: Revenue to Net Income (2007-2011)
Figure 2: AstraZeneca PLC: Revenue/Employee to Net Income/Employee (2007-2011)
Figure 3: AstraZeneca PLC: Current Assets to Current Liabilities (2007-2011)
Figure 4: AstraZeneca PLC: Assets, Liabilities to Total Equity (2007-2011)
Figure 5: AstraZeneca PLC: Free Cash Flow to Cash from Operating Activities (2007-2011)
Figure 6: AstraZeneca PLC: Net Change in Cash (2007-2011)
Figure 7: AstraZeneca PLC: Market Capitalization to Year-end Share Price (2007-2011)
Figure 8: AstraZeneca PLC: Enterprise Value (2007-2011)
Figure 9: AstraZeneca PLC: Deal Activity by Deal Type - Volume (TTM*)
Figure 10: AstraZeneca PLC: M&A Activity by Geography (TTM*)
Figure 11: AstraZeneca PLC: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Figure 12: AstraZeneca PLC: M&A Average Deal Size - Value (US$m)
Figure 13: AstraZeneca PLC: M&A Volume and Value Trend (2009 - YTD*2013)
Figure 14: AstraZeneca PLC: M&A Activity by Geography (2009 - YTD*2013)
Figure 15: AstraZeneca PLC: Partnership Volume and Value Trend (2009 - YTD*2013)
Figure 16: AstraZeneca PLC: Partnership Trend by Deal Type (2009 - YTD*2013)
Figure 17: AstraZeneca PLC: Divestments Volume and Value Trend (2009 - YTD*2013)
Figure 18: AstraZeneca PLC: Divestments by Geography (2009 - YTD*2013)
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.